Patients receiving BENLYSTA + ST were 61% less likely to progress to a higher SDI score over any given year of follow-up compared with patients on standard therapy alone.
Hazard ratio (95% CI): 0.39 (0.25, 0.61)
Results are descriptive.
Real-world studies cannot definitively establish causality and are designed to evaluate associations. Limitations are important to interpret results: post hoc, retrospective analysis; patients matched only on known variables; unmatched variables exist (eg, year of entry, patient populations, and data collection vs randomized controlled trials).
¶Includes all patients with ≥1 year of follow-up.